[ad_1]
London, March 15
In the wake of several European countries discontinuing use of the AstraZeneca Covid-19 vaccine, the company has said there has been no evidence of an increased risk of blood clots from its injection.
The suspensions came amid several reports of blood clots after vaccines with the Covid jab developed by the British-Swedish pharmaceutical giant and the University of Oxford.
“Safety is of the utmost importance and the company is continually monitoring the safety of its vaccine,” the company said in a statement Sunday.
“A careful review of all available safety data from more than 17 million people vaccinated in the European Union (EU) and UK with the COVID-19 AstraZeneca vaccine has shown no evidence of an increased risk of pulmonary embolism, thrombosis deep vein (DVT) or thrombocytopenia, in any defined age group, gender, lot or in any particular country, “he added.
So far in the EU and the UK, 15 episodes of DVT (a condition arising from the formation of a blood clot in a vein) and 22 episodes of pulmonary embolism (blockage of one of the pulmonary arteries in the lungs) have been reported. lungs due to blood clots). among those who received the vaccine, based on the number of cases the company has received as of March 8, AstraZeneca said.
The company said this is much lower than what would be expected to occur naturally in a general population of this size and is similar in other licensed Covid-19 vaccines.
“Around 17 million people in the EU and UK have received our vaccine, and the number of cases of blood clots reported in this group is less than the hundreds of cases that would be expected in the general population”, Ann Taylor , AstraZeneca’s official medical director, said in a statement.
“The nature of the pandemic has led to increased attention in individual cases and we are going beyond standard practices for monitoring the safety of authorized drugs when reporting vaccine events, to ensure public safety.” In terms of quality, there are also no confirmed problems related to any batch of our vaccine used in Europe or the rest of the world, the company said.
The additional tests have been and are being carried out by ourselves and independently by the European health authorities, and none of these new tests have shown cause for concern, he added.
IANS
[ad_2]
